388 related articles for article (PubMed ID: 22927417)
1. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
Zoppoli G; Regairaz M; Leo E; Reinhold WC; Varma S; Ballestrero A; Doroshow JH; Pommier Y
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15030-5. PubMed ID: 22927417
[TBL] [Abstract][Full Text] [Related]
2. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (
Tang SW; Thomas A; Murai J; Trepel JB; Bates SE; Rajapakse VN; Pommier Y
Clin Cancer Res; 2018 Apr; 24(8):1944-1953. PubMed ID: 29391350
[No Abstract] [Full Text] [Related]
3. DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs.
Li M; Kao E; Malone D; Gao X; Wang JYJ; David M
Nat Struct Mol Biol; 2018 Nov; 25(11):1047-1058. PubMed ID: 30374083
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
[TBL] [Abstract][Full Text] [Related]
5. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
Coussy F; El-Botty R; Château-Joubert S; Dahmani A; Montaudon E; Leboucher S; Morisset L; Painsec P; Sourd L; Huguet L; Nemati F; Servely JL; Larcher T; Vacher S; Briaux A; Reyes C; La Rosa P; Lucotte G; Popova T; Foidart P; Sounni NE; Noel A; Decaudin D; Fuhrmann L; Salomon A; Reyal F; Mueller C; Ter Brugge P; Jonkers J; Poupon MF; Stern MH; Bièche I; Pommier Y; Marangoni E
Sci Transl Med; 2020 Feb; 12(531):. PubMed ID: 32075943
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq.
Takashima T; Sakamoto N; Murai J; Taniyama D; Honma R; Ukai S; Maruyama R; Kuraoka K; Rajapakse VN; Pommier Y; Yasui W
Virchows Arch; 2021 Mar; 478(3):569-579. PubMed ID: 32474729
[TBL] [Abstract][Full Text] [Related]
7. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
[TBL] [Abstract][Full Text] [Related]
8. Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
Tian L; Song S; Liu X; Wang Y; Xu X; Hu Y; Xu J
Anticancer Drugs; 2014 Nov; 25(10):1175-81. PubMed ID: 25089570
[TBL] [Abstract][Full Text] [Related]
9. SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents).
Luan J; Gao X; Hu F; Zhang Y; Gou X
J Drug Target; 2020 Jan; 28(1):33-40. PubMed ID: 31092045
[TBL] [Abstract][Full Text] [Related]
10. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
Marzi L; Szabova L; Gordon M; Weaver Ohler Z; Sharan SK; Beshiri ML; Etemadi M; Murai J; Kelly K; Pommier Y
Clin Cancer Res; 2019 Oct; 25(20):6206-6216. PubMed ID: 31409613
[TBL] [Abstract][Full Text] [Related]
11. Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress.
Murai J; Zhang H; Pongor L; Tang SW; Jo U; Moribe F; Ma Y; Tomita M; Pommier Y
Cell Rep; 2020 Mar; 30(12):4137-4151.e6. PubMed ID: 32209474
[TBL] [Abstract][Full Text] [Related]
12. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
Murai J; Thomas A; Miettinen M; Pommier Y
Pharmacol Ther; 2019 Sep; 201():94-102. PubMed ID: 31128155
[TBL] [Abstract][Full Text] [Related]
13. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers.
Zhang B; Ramkumar K; Cardnell RJ; Gay CM; Stewart CA; Wang WL; Fujimoto J; Wistuba II; Byers LA
Br J Cancer; 2021 Nov; 125(10):1333-1340. PubMed ID: 34294893
[TBL] [Abstract][Full Text] [Related]
14. Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer.
Ballestrero A; Bedognetti D; Ferraioli D; Franceschelli P; Labidi-Galy SI; Leo E; Murai J; Pommier Y; Tsantoulis P; Vellone VG; Zoppoli G
J Transl Med; 2017 Oct; 15(1):199. PubMed ID: 28969705
[TBL] [Abstract][Full Text] [Related]
15. Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes.
Onji H; Murai J
Cancer Sci; 2022 Sep; 113(9):2943-2951. PubMed ID: 35766436
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Willis SE; Winkler C; Roudier MP; Baird T; Marco-Casanova P; Jones EV; Rowe P; Rodriguez-Canales J; Angell HK; Ng FSL; Waring PM; Hodgson D; Ledermann JA; Weberpals JI; Dean E; Harrington EA; Barrett JC; Pierce AJ; Leo E; Jones GN
Br J Cancer; 2021 Dec; 125(12):1666-1676. PubMed ID: 34663950
[TBL] [Abstract][Full Text] [Related]
17. Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
Shee K; Wells JD; Jiang A; Miller TW
PLoS One; 2019; 14(11):e0224267. PubMed ID: 31682620
[TBL] [Abstract][Full Text] [Related]
18. FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11.
Yin YP; Ma LY; Cao GZ; Hua JH; Lv XT; Lin WC
Acta Pharmacol Sin; 2022 Aug; 43(8):2119-2127. PubMed ID: 34893686
[TBL] [Abstract][Full Text] [Related]
19. SLFN11 Blocks Stressed Replication Forks Independently of ATR.
Murai J; Tang SW; Leo E; Baechler SA; Redon CE; Zhang H; Al Abo M; Rajapakse VN; Nakamura E; Jenkins LMM; Aladjem MI; Pommier Y
Mol Cell; 2018 Feb; 69(3):371-384.e6. PubMed ID: 29395061
[TBL] [Abstract][Full Text] [Related]
20. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
Conteduca V; Ku SY; Puca L; Slade M; Fernandez L; Hess J; Bareja R; Vlachostergios PJ; Sigouros M; Mosquera JM; Sboner A; Nanus DM; Elemento O; Dittamore R; Tagawa ST; Beltran H
Mol Cancer Ther; 2020 May; 19(5):1157-1164. PubMed ID: 32127465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
